These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 27866515)
1. [Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel Administrated Every Three Weeks in Inoperable Advanced Non-small Cell Lung Cancer: A Retrospective Study from A Single Center]. Zhao J; Zhang X; Hu K; Wang H; Xu Y; Si X; Zhong W; Huang X; Zhang L; Wang M Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):731-737. PubMed ID: 27866515 [TBL] [Abstract][Full Text] [Related]
2. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer]. Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022 [TBL] [Abstract][Full Text] [Related]
3. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. Liew MS; Sia J; Starmans MH; Tafreshi A; Harris S; Feigen M; White S; Zimet A; Lambin P; Boutros PC; Mitchell P; John T Cancer Med; 2013 Dec; 2(6):916-24. PubMed ID: 24403265 [TBL] [Abstract][Full Text] [Related]
4. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739 [TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655 [TBL] [Abstract][Full Text] [Related]
6. Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy. Trinh H; Pinkham MB; Lehman M; Zarate D; Dauth M; McGrath M; McCaffrey E; Mai GT; Horwood K Clin Respir J; 2016 Jul; 10(4):428-34. PubMed ID: 25353367 [TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. Ozcelik M; Korkmaz T; Odabas H; Gemici C; Ercelep O; Yuksel S; Mert AG; Surmeli H; Isik D; Aydin D; Seker M; Mayadagli A; Ozdemir P; Aliustaoglu M; Gumus M Tumour Biol; 2016 Jul; 37(7):8901-7. PubMed ID: 26753955 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970 [TBL] [Abstract][Full Text] [Related]
9. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer. Carter DL; Garfield D; Hathorn J; Mundis R; Boehm KA; Ilegbodu D; Asmar L; Reynolds C Clin Lung Cancer; 2012 May; 13(3):205-13. PubMed ID: 22138037 [TBL] [Abstract][Full Text] [Related]
10. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer]. Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842 [TBL] [Abstract][Full Text] [Related]
12. A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly. Chen YM; Perng RP; Tsai CM; Whang-Peng J J Thorac Oncol; 2006 Feb; 1(2):141-5. PubMed ID: 17409843 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR; J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656 [TBL] [Abstract][Full Text] [Related]
14. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report. Ratanatharathorn V; Lorvidhaya V; Kraipiboon P; Sirachainan E; Maoleekoonpairoj S; Phromratanapongse P; Cheirsilpa A; Tangkaratt S; Srimuninnimit V; Pattaranutaporn P; Lertsanguansinchai P J Med Assoc Thai; 2000 Jan; 83(1):85-92. PubMed ID: 10710874 [TBL] [Abstract][Full Text] [Related]
16. First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China. Chang Q; Zhang Y; Xu J; Zhong R; Qiang H; Zhang B; Han B; Qian J; Chu T Thorac Cancer; 2019 May; 10(5):1043-1050. PubMed ID: 30900826 [TBL] [Abstract][Full Text] [Related]
17. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. Langer CJ; O'Byrne KJ; Socinski MA; Mikhailov SM; Leśniewski-Kmak K; Smakal M; Ciuleanu TE; Orlov SV; Dediu M; Heigener D; Eisenfeld AJ; Sandalic L; Oldham FB; Singer JW; Ross HJ J Thorac Oncol; 2008 Jun; 3(6):623-30. PubMed ID: 18520802 [TBL] [Abstract][Full Text] [Related]
18. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer]. Li DX; Chen XB Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Wang L; Wu S; Ou G; Bi N; Li W; Ren H; Cao J; Liang J; Li J; Zhou Z; Lv J; Zhang X Lung Cancer; 2012 Jul; 77(1):89-96. PubMed ID: 22418243 [TBL] [Abstract][Full Text] [Related]
20. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Choy H; Akerley W; Safran H; Graziano S; Chung C; Williams T; Cole B; Kennedy T J Clin Oncol; 1998 Oct; 16(10):3316-22. PubMed ID: 9779707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]